Novan Inc

NOVN

NASDAQ. Currency in USD

1.13 -0.13 ( -10.32% )

Real time prices: December 19

Market Cap.
27.64M
Beta (5Y monthly)
0.29
Price/Earnings
-
EPS (TTM)
-2.02
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
208,052
1y Target Est.
14.50
Day's Range
1.13
-
1.26
52 Week's Range
0.79
-
4.36

Historical Summary

Performance
EPS growth
Share Buybacks

About Novan Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.novan.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
18.82M
Employees
29
Address
4020 Stirrup Creek Drive, Durham, NC, United States, 27703
Novan, Inc., a medical dermatology company, focuses on researching, developing, and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Latest news

Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5

Basel, December 13, 2022 — Novartis today announced detailed results from the pivotal Phase III...
By GlobeNewswire Inc. - 6 weeks ago

Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH

Basel, December 8, 2022 — Novartis today announced the Phase III APPOINT-PNH study (NCT04820530) of...
By GlobeNewswire Inc. - 7 weeks ago

Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy

Basel, December 6, 2022 — Novartis today announced results from the RIGHT Choice Phase II...
By GlobeNewswire Inc. - 7 weeks ago

Novartis prostate cancer drug trial meets primary endpoint
Novartis prostate cancer drug trial meets primary endpoint

The data will be submitted for regulatory approval next year to the U.S. Food and...
By MarketWatch - 8 weeks ago

EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement
EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement

– Agreement provides immediate access to cash flow –
By GlobeNewswire Inc. - 8 weeks ago

New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years
New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four years

Basel, November 7, 2022 — Novartis today announced results from the Phase II open-label extension...
By GlobeNewswire Inc. - 12 weeks ago